Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1385P - Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Zhao-qing Tang

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

Z. Tang1, Y. Wang2, D. Liu3, Y. Yu2, Y. Cui2, C. Tang2, J. Sun4, Q. Zhang4, Y. Ji5, G. Ma4, Z. Shen3, F. Liu3, K. Shen3, X. Wang1, T. Liu2, Y. Sun3

Author affiliations

  • 1 Department Of General Surgery, Zhongshan Hospital, 200032 - Shanghai/CN
  • 2 Department Of Medical Oncology, Zhongshan Hospital, Shanghai/CN
  • 3 Department Of General Surgery, Zhongshan Hospital, Shanghai/CN
  • 4 Department Of Radiotherapy, Zhongshan Hospital, Shanghai/CN
  • 5 Department Of Pathology, Zhongshan Hospital, Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1385P

Background

Recent results from several clinical trials evaluating chemoimmunotherapy combination as neoadjuvant therapy have shown improved pathologic complete response (pCR) in some cancer types other than PGC. Thus, the phase II study (Neo-PLANET) was conducted to evaluate the efficacy and safety of camrelizumab plus chemoradiation as neoadjuvant therapy for locally advanced PGC.

Methods

Eligible patients with proximal gastric adenocarcinoma (cT3-4aN+M0) received sequentially one cycle of XELOX regimen (oxaliplatin 130mg/m2 iv d1 and capecitabine 1000mg/m2 po bid d1-14), chemoradiotherapy (45Gy/25 fractions, capecitabine 850mg/m2 po bid for five weeks) followed by one cycle of XELOX, along with five cycles of camrelizumab (200 mg iv, q3w) throughout neoadjuvant therapy. After radical surgery, they were advised to receive four cycles of XELOX. The primary endpoint was pCR rate. Secondary endpoints included major pathologic response (MPR) rate, progression-free survival,overall survival, and safety profile.

Results

A total of 36 patients were included with a median age of 65.5 years (range 35-72). Most of patients (77.8%) were male, 86.1% had cT4a, and 52.8% of primary tumors located at the gastroesophageal junction, others at gastric body. Beyond one patient with liver metastasis, one with peritoneal metastasis and one patient who refused surgery, 33 patients underwent radical surgery. R0 resection rate was 91.7%, 12 patients achieved pCR (33.3%) and MPR rate was 41.7%. The most common treatment emergent adverse events (TEAEs) of any grade included lymphocyte count decreased (97.2%), anemia (88.9%), white blood cell decreased (72.2%), and reactive capillary hyperplasia (69.4%). Twenty-seven patient (75%) experienced grade 3-4 lymphocyte count decreased.

Conclusions

Camrelizumab combined chemoradiation in the neoadjuvant setting showed promising results in patients with locally advanced PGC, and further investigation is warranted in a phase III clinical trial.

Clinical trial identification

NCT03631615.

Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.